# Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis

> **NCT06109818** · PHASE2 · COMPLETED · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 129 (actual)

## Conditions studied

- Moderate to Severe Plaque Psoriasis

## Interventions

- **DRUG:** ICP-488 Tablets
- **DRUG:** ICP-488 Placebo

## Key facts

- **NCT ID:** NCT06109818
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-04
- **Primary completion:** 2024-08-05
- **Final completion:** 2024-09-18
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06109818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06109818, "Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06109818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*